drugset / Trial / NCT07677293
Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases
Timeline
- Start
- 2026-06-26
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 1800 mg | — |
| Comparator | Sintilimab | Monoclonal antibody | — | — |
| Comparator | Tislelizumab | Monoclonal antibody | — | — |
| Comparator | Capecitabine | Small molecule | — | — |
| Comparator | Oxaliplatin | Small molecule | — | — |